PMID- 37146918
OWN - NLM
STAT- MEDLINE
DCOM- 20230605
LR  - 20230606
IS  - 1879-260X (Electronic)
IS  - 0925-4439 (Linking)
VI  - 1869
IP  - 6
DP  - 2023 Aug
TI  - Advanced nanoscale drug delivery systems for bone cancer therapy.
PG  - 166739
LID - S0925-4439(23)00105-9 [pii]
LID - 10.1016/j.bbadis.2023.166739 [doi]
AB  - Bone tumors are relatively rare, which are complex cancers and primarily involve 
      the long bones and pelvis. Bone cancer is mainly categorized into osteosarcoma 
      (OS), chondrosarcoma, and Ewing sarcoma. Of these, OS is the most intimidating 
      cancer of the bone tissue, which is mostly found in the log bones in young 
      children and older adults. Conspicuously, the current chemotherapy modalities 
      used for the treatment of OS often fail mainly due to (i) the non-specific 
      detrimental effects on normal healthy cells/tissues, (ii) the possible emergence 
      of drug resistance mechanisms by cancer cells, and (iii) difficulty in the 
      efficient delivery of anticancer drugs to the target cells. To impose the maximal 
      therapeutic impacts on cancerous cells, it is of paramount necessity to 
      specifically deliver chemotherapeutic agents to the tumor site and target the 
      diseased cells using advanced nanoscale multifunctional drug delivery systems 
      (DDSs) developed using organic and inorganic nanoparticles (NPs). In this review, 
      we provide deep insights into the development of various DDSs applied in 
      targeting and eradicating OS. We elaborate on different DDSs developed using 
      biomaterials, including chitosan, collagen, poly(lactic acid), 
      poly(lactic-co-glycolic acid), polycaprolactone, poly(ethylene glycol), polyvinyl 
      alcohol, polyethyleneimine, quantum dots, polypeptide, lipid NPs, and exosomes. 
      We also discuss DDSs established using inorganic nanoscale materials such as 
      magnetic NPs, gold, zinc, titanium NPs, ceramic materials, silica, silver NPs, 
      and platinum NPs. We further highlight anticancer drugs' role in bone cancer 
      therapy and the biocompatibility of nanocarriers for OS treatment.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Amiryaghoubi, Nazanin
AU  - Amiryaghoubi N
AD  - Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
FAU - Fathi, Marziyeh
AU  - Fathi M
AD  - Research Center for Pharmaceutical Nanotechnology, Biomedicine Institute, Tabriz 
      University of Medical Sciences, Tabriz, Iran.
FAU - Barar, Jaleh
AU  - Barar J
AD  - Department of Pharmaceutical Sciences, Barry and Judy Silverman College of 
      Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USA.
FAU - Omidian, Hossein
AU  - Omidian H
AD  - Department of Pharmaceutical Sciences, Barry and Judy Silverman College of 
      Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USA.
FAU - Omidi, Yadollah
AU  - Omidi Y
AD  - Department of Pharmaceutical Sciences, Barry and Judy Silverman College of 
      Pharmacy, Nova Southeastern University, Fort Lauderdale, FL 33328, USA. 
      Electronic address: yomidi@nova.edu.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230503
PL  - Netherlands
TA  - Biochim Biophys Acta Mol Basis Dis
JT  - Biochimica et biophysica acta. Molecular basis of disease
JID - 101731730
RN  - 0 (Antineoplastic Agents)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
SB  - IM
MH  - Child
MH  - Humans
MH  - Child, Preschool
MH  - Aged
MH  - Drug Delivery Systems
MH  - *Antineoplastic Agents/pharmacology/therapeutic use
MH  - Polyethylene Glycols
MH  - *Bone Neoplasms/drug therapy
MH  - *Osteosarcoma
OTO - NOTNLM
OT  - Biomaterials
OT  - Bone cancer
OT  - Drug delivery systems
OT  - Nanomaterials
OT  - Osteosarcoma
OT  - Tumor targeting
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/05/06 09:42
MHDA- 2023/06/05 06:42
CRDT- 2023/05/05 19:29
PHST- 2023/01/16 00:00 [received]
PHST- 2023/04/08 00:00 [revised]
PHST- 2023/04/27 00:00 [accepted]
PHST- 2023/06/05 06:42 [medline]
PHST- 2023/05/06 09:42 [pubmed]
PHST- 2023/05/05 19:29 [entrez]
AID - S0925-4439(23)00105-9 [pii]
AID - 10.1016/j.bbadis.2023.166739 [doi]
PST - ppublish
SO  - Biochim Biophys Acta Mol Basis Dis. 2023 Aug;1869(6):166739. doi: 
      10.1016/j.bbadis.2023.166739. Epub 2023 May 3.